Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CMMB Chemomab Therapeutics Ltd
- Stocks
- Healthcare
- NASDAQ: CMMB
Price (delayed)
$1.37
Market cap
$25.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.66
Enterprise value
$17.66M
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of
Highlights
CMMB's EPS has surged by 58% year-on-year and by 15% since the previous quarter
CMMB's quick ratio is up by 39% YoY and by 7% from the previous quarter
CMMB's equity is down by 23% from the previous quarter and by 22% YoY
Key stats
What are the main financial stats of CMMB
Market
Valuations
Earnings
Shares outstanding
18.86M
Market cap
$25.84M
Enterprise value
$17.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.49
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$14.18M
Net income
-$13.4M
EBIT
-$13.4M
EBITDA
N/A
Free cash flow
N/A
Per share
Balance sheet
Liquidity
EPS
-$0.66
EPS diluted
-$0.66
Free cash flow per share
N/A
Book value per share
$0.55
Revenue per share
$0
TBVPS
$0.56
Total assets
$12.82M
Total liabilities
$2.43M
Debt
$292,000
Equity
$10.39M
Working capital
$9.73M
Debt to equity
0.03
Current ratio
5.33
Quick ratio
5.33
Net debt/EBITDA
N/A
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-82.2%
Return on equity
-106.7%
Return on invested capital
-206.1%
Return on capital employed
-126.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMMB stock price
How has the Chemomab Therapeutics stock price performed over time
Intraday
6.2%
1 week
8.73%
1 month
18.1%
1 year
57.47%
YTD
-24.31%
QTD
25.69%
Financial performance
How have Chemomab Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.18M
Net income
-$13.4M
Gross margin
N/A
Net margin
N/A
Chemomab Therapeutics's operating income has increased by 31% YoY and by 3.8% from the previous quarter
CMMB's net income is up by 31% year-on-year and by 3.9% since the previous quarter
Price vs fundamentals
How does CMMB's price correlate with its fundamentals
Growth
What is Chemomab Therapeutics's growth rate over time
Valuation
What is Chemomab Therapeutics stock price valuation
P/E
N/A
P/B
2.49
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CMMB's EPS has surged by 58% year-on-year and by 15% since the previous quarter
CMMB's price to book (P/B) is 108% more than its 5-year quarterly average of 1.2 and 38% more than its last 4 quarters average of 1.8
CMMB's equity is down by 23% from the previous quarter and by 22% YoY
Efficiency
How efficient is Chemomab Therapeutics business performance
Chemomab Therapeutics's return on invested capital has decreased by 22% QoQ
The return on assets has declined by 3.8% since the previous quarter
CMMB's return on equity is up by 2.9% year-on-year
Dividends
What is CMMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMMB.
Financial health
How did Chemomab Therapeutics financials performed over time
The total liabilities has declined by 48% year-on-year and by 29% since the previous quarter
CMMB's quick ratio is up by 39% YoY and by 7% from the previous quarter
The debt is 97% lower than the equity
CMMB's debt to equity has soared by 50% from the previous quarter
The debt is down by 25% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.